Piscidin-1 Induces Apoptosis via Mitochondrial Reactive Oxygen Species-Regulated Mitochondrial Dysfunction in Human
Meng-Hsuan Cheng1,2,3, Chieh-Yu Pan4, Nan-Fu Chen5,6
1Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, 80756, Taiwan.
Abstract:
Osteosarcoma (OSA) is the most common type of cancer that originates in the bone and usually occurs in young children. OSA patients were treated with neoadjuvant chemotherapy and surgery, and the results were disappointing. Marine antimicrobial peptides (AMPs) have been the focus of antibiotic research because they are resistant to pathogen infection. Piscidin-1 is an AMP from the hybrid striped bass (Morone saxatilis × M. chrysops) and has approximately 22 amino acids. Research has shown that piscidin-1 can inhibit bacterial infections and has antinociception and anti-cancer properties; however, the regulatory effects of piscidin-1 on mitochondrial dysfunction in cancer cells are still unknown. We aimed to identify the effects of piscidin-1 on mitochondrial reactive oxygen species (mtROS) and apoptosis in OSA cells. Our analyses indicated that piscidin-1 has more cytotoxic effects against OSA cells than against lung and ovarian cancer cells; however, it has no effect on non-cancer cells. Piscidin-1 induces apoptosis in OSA cells, regulates mtROS, reduces mitochondrial antioxidant manganese superoxide dismutase and mitochondrial transmembrane potential, and decreases adenosine 5'-triphosphate production, thus leading to mitochondrial dysfunction and apoptosis. The mitochondrial antioxidant, mitoTempo, reduces the apoptosis induced by piscidin-1. Results suggest that piscidin-1 has potential for use in OSA treatment.
Insights
Piscidin-1, a marine antimicrobial peptide, effectively targets osteosarcoma cells by inducing apoptosis and mitochondrial dysfunction. This peptide shows promise as a novel therapeutic agent for bone cancer treatment.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Osteosarcoma (OSA) is a primary bone cancer predominantly affecting children, with current treatments yielding suboptimal outcomes.
- Marine antimicrobial peptides (AMPs) are explored for their therapeutic potential, including anti-cancer properties.
- The specific effects of Piscidin-1 on mitochondrial function in OSA remain largely uncharacterized.
Purpose of the Study:
- To investigate the impact of Piscidin-1 on mitochondrial reactive oxygen species (mtROS) and apoptosis in osteosarcoma cells.
- To determine the selectivity of Piscidin-1 against OSA cells compared to other cancer types and non-cancerous cells.
Main Methods:
- In vitro assessment of Piscidin-1's cytotoxic effects on various cancer and non-cancer cell lines.
- Analysis of mtROS levels, apoptosis markers, mitochondrial transmembrane potential, and adenosine 5'-triphosphate (ATP) production in OSA cells treated with Piscidin-1.
- Evaluation of the protective effect of the antioxidant mitoTempo against Piscidin-1-induced apoptosis.
Main Results:
- Piscidin-1 demonstrated significant cytotoxicity towards OSA cells, with minimal impact on lung, ovarian, and non-cancer cells.
- Piscidin-1 treatment led to increased apoptosis in OSA cells, accompanied by regulation of mtROS.
- Piscidin-1 reduced manganese superoxide dismutase, mitochondrial transmembrane potential, and ATP production, indicating induced mitochondrial dysfunction.
Conclusions:
- Piscidin-1 effectively induces apoptosis and mitochondrial dysfunction in osteosarcoma cells.
- The observed effects suggest Piscidin-1's potential as a targeted therapeutic agent for osteosarcoma.
- MitoTempo mitigated Piscidin-1-induced apoptosis, further supporting the role of mitochondrial pathways in its mechanism of action.
Related Concept Videos
The Intrinsic Apoptotic Pathway
The Extrinsic Apoptotic Pathway
Caspases
PI3K/mTOR/AKT Signaling Pathway
Abnormal Proliferation
The JAK-STAT Signaling Pathway


